Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Astellas Pharma ( (JP:4503) ).
Astellas Pharma and Pfizer announced pivotal Phase 3 trial results for PADCEV combined with Keytruda, marking a significant advancement in muscle-invasive bladder cancer treatment. The trial highlights considerable survival improvement without platinum-based chemotherapy, potentially redefining the standard of care for patients both eligible and ineligible for cisplatin, offering hope for better outcomes and impacting the oncology landscape.
The most recent analyst rating on (JP:4503) stock is a Hold with a Yen2271.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas Pharma is a global pharmaceutical company focused on innovative and advanced therapies across various therapeutic areas, including oncology. The company works to provide groundbreaking treatment options, often collaborating with other prominent organizations in the healthcare sector.
Average Trading Volume: 8,354,211
Technical Sentiment Signal: Buy
Current Market Cap: Yen3828.4B
For an in-depth examination of 4503 stock, go to TipRanks’ Overview page.